AHZ shouldn't need to partner. As Cardiocel uptake spreads, cashflow should be sufficient to fund the vaccines. Also,with income, a bank loan could be taken out at less than the shareholders' expected return if capital was required. IMO, its all about Cardiocel. If successful, we won't have to go through anymore capital raisings. As sales data comes in over the next 2 years, we should see the SP on a steady upward trend. Add in a new cardiocel spin off product and/or the vaccine story improving, and we have the signs of a company that should be around for a while.
Ann: Admedus to showcase CardioCel at EACTS Annual Meeting, page-58
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |